A total of 130 patients with liver cirrhosis who fulfill the criteria of the study, and who
have been found to have left ventricular diastolic dysfunction on a screening 2D
echocardiography, will then be randomized by Block randomization technique, to two arms in a
ratio 1:1(Group A) will receive carvedilol+ Ivabradine targeted therapy for heart rate
reduction while Group B will receive Carvedilol alone; and the dosage of drug in the
treatment arm will be titrated every week to achieve target heart rate of 50-60/ minute.
Patients in the treatment arms, who are unable to tolerate carvedilol due to hypotension
episodes, will be offered ivabradine alone to allow achievement of targeted heart rate
reduction. All patients will be evaluated at 0,6, and 12 months. The end points will be
clinical events, cardiac function improvement, renal function, and mortality.
Phase:
N/A
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research